Clinical trials: Schizophrenia Patients
Schizophrenia
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
- Trial name
- NCT01529515
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 53 sites in United States, Colombia and 6 more
- Volunteers
- 509 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics
To evaluate the QOL (subjective effectiveness) in patients with schizophrenia, treated with atypical antipsychotics.
- Trial name
- Xperience (NCT00689325)
- Where
- 37 sites in Netherlands
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Schizophrenia
Safety and Tolerability of Risperidone Implants
A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
- Trial name
- NCT02773576
- Testing
- Risperidone implant
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Braeburn Pharmaceuticals
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
MIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of roluperidone in adult schizophrenia patients.The primary objective is to…
- Trial name
- NCT03397134
- Testing
- Roluperidone 32 mg, Roluperidone 64 mg
- Where
- 39 sites in United States, Bulgaria and 2 more
- Volunteers
- 515 people
- Sponsor
- Minerva Neurosciences
SCHIZOPHRENIA 1 (Disorder)
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia
This is a Phase 2b, randomized, double-blind, parallel-group, active-controlled and placebo-controlled, multicenter inpatient study to examine the efficacy and safety of HS-10380 in adult Participants who are acutely psychotic…
- Trial name
- NCT07550387
- Testing
- HS-10380 Low Dose, HS-10380 Medium dose, HS-10380 High Dose
- Where
- China
- Volunteers
- 363 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Tardive Dyskinesia
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
The primary objective is to assess the safety and effectiveness of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of tardive dyskinesia in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00917293
- Testing
- Pyridoxal 5'-Phosphate
- Where
- 4 sites in Canada, India
- Volunteers
- 53 people
- Sponsor
- Medicure
Schizophrenia
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
The phase 3 Trial 31-12-291 is part of the aripiprazole IM depot clinical development program and has been designed to demonstrate the efficacy and safety of aripiprazole IM depot for the treatment of adults experiencing an acute…
- Trial name
- NCT01683058
- Testing
- Aripiprazole IM Depot
- Where
- 38 sites in United States, Croatia and 1 more
- Volunteers
- 74 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Cognitive Impairment
Study of ALTO-101 in Patients With Schizophrenia
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition.
- Trial name
- NCT06502964
- Testing
- ALTO-101, ALTO-101 Transdermal Delivery System
- Where
- 14 sites in United States
- Volunteers
- 82 people
- Sponsor
- Alto Neuroscience
Schizophrenia
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
This will be a randomized, double-blind, placebo-controlled study consisting of a screening period, a conversion phase (Phase 1), a stabilization phase (Phase 2), and a double-blind maintenance treatment phase (Phase 3), and a…
- Trial name
- ATTAIN 266 (NCT01149655)
- Testing
- Aripiprazole
- Where
- 52 sites in United States, India and 5 more
- Volunteers
- 252 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Comparison of the Effectiveness of Brexpiprazole With That of Risperidone
To demonstrate that the effectiveness of brexpiprazole (2-4 mg/day) on quality of life is non-inferior to that of risperidone (4-6 mg/day) in adult patients with schizophrenia.
- Trial name
- TAILWIND (NCT02758067)
- Testing
- brexpiprazole, risperidone
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
To assess the effect of zicronapine versus risperidone on metabolic parameters comprising body weight, body mass index (BMI), waist circumference, levels of fasting blood lipids and glucose during 6 months of treatment.
- Trial name
- NCT01295372
- Testing
- Zicronapine, Risperidone
- Where
- 24 sites in Czechia, Estonia and 3 more
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizoaffective Disorder
Seroquel Long-Term NIS for Schizophrenia Patients
To assess the efficacy of 24-week treatment with quetiapine in patients with schizophrenia or schizoaffective disorder
- Trial name
- SELECT (NCT00523783)
- Where
- 3 sites in South Korea
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Negative Symptoms in Schizophrenia
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
The goal of this clinical trial is to evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects with Moderate to Severe Negative Symptoms…
- Trial name
- NCT06107803
- Testing
- Roluperidone 64 mg, Olanzapine 10 MG
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Minerva Neurosciences
Schizophrenia
Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)
The primary objective of this study is to determine if Australian patients with schizophrenia treated with paliperidone palmitate under conditions of continuous monitoring of outcomes over a 12-month period achieve relapse rates…
- Trial name
- NCT01362426
- Testing
- paliperidone palmitate
- Where
- 10 sites in Australia
- Volunteers
- 127 people
- Sponsor
- Janssen-Cilag Pty Ltd
Schizophrenia, Bipolar Disorder
A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder
The purpose of this study is to evaluate the potential effect of multiple oral doses of an extended release formulation of paliperidone on the pharmacokinetics (blood levels) of valproic acid (VPA) in patients with schizophrenia…
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT01094249
- Testing
- divalproex sodium ER/paliperidone ER
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013).
- Trial name
- NCT05211947
- Testing
- Iclepertin
- Where
- 303 sites in United States, Argentina and 38 more
- Volunteers
- 1,356 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
A Study of ANAVEX3-71 in Adults With Schizophrenia
A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
- Trial name
- SZ-001 (NCT06245213)
- Testing
- ANAVEX3-71 oral capsules
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Anavex Life Sciences Corp.
Cognitive Impairment Associated With Schizophrenia
Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
To establish the proof of concept that MEM 3454, used as add-on pharmacotherapy, is a safe and effective treatment in patients with cognitive impairment associated with schizophrenia (CIAS).
- Trial name
- NCT00604760
- Testing
- MEM 3454
- Where
- 44 sites in United States
- Volunteers
- 160 people
- Sponsor
- Memory Pharmaceuticals
Psychosis
An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)
This trial was a randomized trial to determine a patient's acceptability of unflavored antipsychotic medication compared to raspberry flavored antipsychotic medication.
- Trial name
- NCT00878462
- Testing
- Asenapine WHITE raspberry flavor (Treatment A), Asenapine RED raspberry flavor (Treatment B), Asenapine WHITE UNFLAVORED (Treatment C)
- Volunteers
- 174 people
- Sponsor
- Organon and Co
Schizophrenia
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of multiple ascending doses of AZD0328 in patients with schizophrenia
- Trial name
- NCT00669903
- Testing
- AZD0328
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca